Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58).

2015 Financial Outlook

Esperion expects that the net cash used to fund operating activities in 2015 will be approximately $42 million and that its cash and cash equivalents and investment securities available-for-sale will total approximately $290 million at December 31, 2015. The Company estimates that current cash resources are sufficient to fund the Company through 2018 and the expected approval of ETC-1002.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.